1. Why California Employers Still Screen for Drugs

Drug testing in California workplaces is not primarily a compliance exercise — it is a safety and liability management tool. Workers' compensation claims, negligent hiring exposure, OSHA recordable incidents, and productivity losses tied to substance impairment represent real costs to California employers across every industry. The California Division of Workers' Compensation processes hundreds of thousands of claims annually, and substance-impaired employees represent a statistically disproportionate share of serious workplace injury events.

Employers who have considered dropping their drug testing programs following AB 2188 have largely concluded the opposite: the law changed which results they can act on, not whether drug use in the workforce is a safety concern. The response from forward-thinking California employers has been to update their programs — adjusting panel configurations, switching to oral fluid for post-accident testing, removing THC from non-exempt programs — rather than abandoning testing altogether.

California private employers are also subject to general duty obligations under Cal/OSHA that require maintaining a workplace free of recognized hazards. An employer who knows that substance impairment is a risk factor in their industry and who has no drug testing program faces meaningful exposure if an impairment-related incident occurs and no program existed to identify or address it.

---

2. California Drug Testing Law in 2027: AB 2188, SB 700, and What Changed

California's drug testing legal framework as of 2027 is shaped primarily by two statutes that took effect January 1, 2024: Assembly Bill 2188 and Senate Bill 700, both codified within the California Fair Employment and Housing Act (FEHA) at Government Code Section 12954.

What AB 2188 Does

AB 2188 prohibits California employers from discriminating against employees or applicants based on their off-duty, off-premises cannabis use. More specifically, it prohibits adverse employment action based on a positive test for non-psychoactive cannabis metabolites — the THC-COOH compounds detected by standard urine and hair immunoassay panels — because those metabolites indicate past exposure, not current impairment.

What SB 700 Adds

SB 700 extended AB 2188's protections to the pre-employment context. Employers may not ask applicants about prior cannabis use and may not use a pre-employment urine or hair test showing THC metabolites as grounds for declining to hire — again, with specific exceptions that preserve testing authority.

The Exceptions — Where THC Testing Is Still Permitted

• Building and construction trades — AB 2188 explicitly exempts the construction industry, meaning California contractors may retain THC in their testing panels.
• Federal contractors and federally regulated employers — Employers subject to federal law, federal contract requirements, or Department of Transportation regulations retain full THC testing authority for covered positions.
• Safety-sensitive positions with a bona fide occupational qualification — Where cannabis impairment would create a direct and present danger to the physical safety of others, employers may document and apply a THC testing requirement.
• Federal background investigations and security clearances — Positions requiring a federal clearance are exempt.
• California state government — State civil service employees are governed separately by the California Department of Human Resources program, which operates under its own authority independent of AB 2188's private-employer restrictions.

Random Drug Testing in California

California courts and the Labor Code place substantial restrictions on suspicionless random drug testing by private employers. Unlike Texas or Florida, California generally requires that random testing be limited to safety-sensitive positions with documented justification, or that it occur under a federal regulatory mandate. California employers should not implement random drug testing programs based solely on a written policy without reviewing whether their workforce classification supports it under California law. Qualified employment counsel review is essential before implementing or expanding a California random testing program.

For California factories, manufacturers, and industrial employers — where the intersection of AB 2188 and workplace safety creates the most operational complexity — our guide to drug testing solutions for California factories: saliva kits and urine cups that support compliance provides a practical operational breakdown.

---

3. THC and Marijuana: Should California Employers Still Test?

The question California employers are wrestling with is not whether cannabis use is a workplace safety concern — it is — but whether the current tools available for detecting THC are well matched to what the law now allows employers to do with those results.

Standard urine and hair immunoassay THC tests detect metabolites — specifically THC-COOH — that persist for days, weeks, or even months after consumption, with no established relationship to current impairment. A positive urine THC result tells an employer that an employee used cannabis at some point in the past. It does not tell the employer whether that employee was impaired at the time of a workplace incident, impaired during work hours, or impaired at all.

AB 2188's restrictions are a direct response to that disconnect. They reflect a legislative judgment that metabolite-based THC results, in the absence of observable impairment, are not a reliable or fair basis for employment decisions. California employers who retain standard THC urine testing should understand that the results generate legal exposure without creating actionable safety information for most non-exempt workforce categories.

The practical adaptation that is gaining ground among California private employers in non-exempt categories: remove THC from the urine panel, use non-THC drug test configurations, and rely on oral fluid saliva testing — which detects recent use rather than metabolites — for post-accident and reasonable suspicion testing scenarios where current impairment is the actual question.

---

4. 5-Panel vs. 10-Panel vs. Expanded Panels: Which Is Right for Your California Program?

California employers have more panel options than most HR teams have explored. The right configuration depends on your industry, your AB 2188 status, and which substances are actually present in your workforce. The chart below compares the most common CLIA-waived urine drug test cup configurations available through DrugScreens.com.

The SAFElife 5-panel C-Cup compact CLIA-waived urine drug test is the standard starting point for most California construction and DOT-adjacent employers. The Healgen 10-panel rapid drug test cup adds prescription drug coverage for healthcare, pharmaceutical, and manufacturing programs. The full SAFElife CLIA-waived urine cup collection and the Healgen urine cup lineup offer expanded panel configurations up to 18-panel for programs that need broader coverage.

---

5. Urine vs. Saliva Drug Testing for California Employers

The specimen type decision has become one of the most operationally significant choices for California employers post-AB 2188. Here is the core distinction that makes oral fluid saliva testing increasingly relevant in California specifically:

Urine tests detect metabolites — chemical byproducts that remain in the body long after the psychoactive effects of a substance have passed. Oral fluid tests detect the parent drug compound present in saliva, with a detection window that closely tracks the period of actual impairment. That distinction is what makes oral fluid testing fall outside AB 2188's metabolite-based restrictions for THC.

For post-accident and reasonable suspicion testing — where the question is whether the employee was impaired at or near the time of the incident — oral fluid is often the superior tool for California employers. The SAFElife 6-panel T-Square saliva screen drug test kit and the 10-panel T-Square saliva screen — both available in employment, insurance, and forensic use classifications — give California employers an observed, portable, adulteration-resistant collection option that targets recent use. The complete SAFElife saliva kit collection and the Healgen saliva drug test lineup provide multi-panel options for California employers with varying program needs.

---

6. Non-THC Drug Test Panels: The Post-AB 2188 Adaptation

The most practical adaptation for California private employers in non-exempt categories has been to remove THC from their urine testing panel entirely. Non-THC drug test cups and dip cards screen for cocaine, methamphetamine, opiates, benzodiazepines, and other substances without generating a THC metabolite result that AB 2188 restricts from use in employment decisions.

This approach has several advantages: it eliminates the legal exposure created by generating a result the employer cannot act on; it simplifies the MRO review process by removing the most ambiguous analyte from the panel; and it allows the employer to maintain a meaningful drug testing program for the substances that are actually associated with on-the-job impairment and safety risk in their workforce.

California staffing agencies, retail and service industry employers, manufacturing operations, and employers in competitive labor markets where THC-inclusive testing creates hiring friction have been the primary adopters of non-THC panel configurations since AB 2188 took effect.

---

7. What Your Drug Test May Be Missing: Emerging Substances in 2027

This is the section most California drug testing programs have not caught up to. The controlled substance landscape has shifted substantially beyond the traditional 5-panel analytes — and standard panels miss several of the substances now showing up in California workforces at meaningful frequency:

Fentanyl — The Gap in Standard Panels

Standard urine opiate strips (OPI/300 or OPI/2000) are calibrated for morphine and codeine. They do not reliably detect fentanyl or its metabolites. Fentanyl is now present in a substantial portion of the illicit drug supply in California, and employees who test negative on a standard 5-panel opiate strip may still be using fentanyl. California employers — particularly in healthcare, logistics, and any industry with known substance misuse prevalence — should strongly consider expanded panel cups that include a dedicated fentanyl (FEN) strip. DrugScreens.com carries 12-panel through 18-panel configurations with FEN detection.

Xylazine — The Companion Adulterant

Xylazine is a veterinary sedative that has been increasingly found as an adulterant mixed into illicit fentanyl supply across California and the Western United States. It is not currently on any standard workplace drug test panel. Laboratory confirmation of fentanyl-positive specimens increasingly includes xylazine screening at the MRO level. California employers whose programs generate confirmatory lab testing should discuss xylazine screening with their MRO provider.

Kratom (Mitragynine / 7-OH)

Kratom is a botanical substance with opioid-receptor activity increasingly used by individuals managing chronic pain, opioid withdrawal, or seeking stimulant effects. It is legal in California and not detected on standard opiate strips. Select expanded panel configurations include mitragynine (MG) or 7-hydroxymitragynine (7-OH) strips for programs where kratom use is a documented concern — particularly addiction recovery programs and sober living operators in California.

Benzodiazepines — The Prescription Drug Gap

The standard 5-panel does not include benzodiazepines. BZO is one of the most commonly misused prescription drug classes in California, with diazepam, alprazolam, clonazepam, and lorazepam all generating impairment profiles comparable to alcohol. For California healthcare employers, patient transport operations, and any safety-sensitive industry where prescription sedative misuse is a workforce concern, a 10-panel or expanded configuration that includes BZO is a meaningful safety upgrade.

Methamphetamine — Elevated in the Western United States

Workplace drug test positivity data consistently shows the Western United States — including California — with above-average methamphetamine prevalence compared to national figures. Standard 5-panel AMP strips screen for amphetamine class broadly; cups with dedicated MET strips provide clearer results and lower cross-reactivity rates. California construction, logistics, and manufacturing employers should evaluate whether their current panel differentiates between amphetamine and methamphetamine.

---

8. Industry Requirements: Construction, Staffing, Healthcare, Transportation

Construction Trades

California construction employers are explicitly exempted from AB 2188's THC restrictions. General contractors, subcontractors, and specialty trades may retain a full 5-panel or 10-panel urine cup including THC. For job-site collection where facilities are limited, oral fluid saliva kits provide a portable, observed-collection option for post-accident and reasonable suspicion testing across active California construction sites.

Staffing Agencies

California staffing agencies face a compounded compliance burden: they must navigate AB 2188 for their own employment relationships while also addressing the drug testing requirements of client employers who may operate under DOT regulations, federal contracts, or industry-specific requirements. Most California staffing agencies have moved to non-THC panel configurations for general placements, with carve-outs for construction and federally regulated client programs.

Healthcare

California healthcare employers — hospitals, skilled nursing facilities, home health agencies, and behavioral health providers — fall within AB 2188's safety-sensitive exception for positions where cannabis impairment creates a direct risk to patients. Healthcare employers also face broader prescription drug misuse risk that makes 10-panel and expanded panel configurations, including BZO, MTD, OXY, and fentanyl strips, the appropriate choice for patient-facing positions.

Transportation and Logistics

California employers in the transportation sector with CDL holders and safety-sensitive positions subject to FMCSA jurisdiction are required to conduct DOT 5-panel urine testing at SAMHSA-certified laboratories. AB 2188 does not apply to federally regulated testing. Non-CDL operations and warehouse or logistics employees not subject to DOT authority are governed by the standard California private-employer framework.

---

9. When to Test: Pre-Employment, Random, Reasonable Suspicion, Post-Accident

• Pre-employment: SB 700 restricts use of pre-employment THC metabolite results for non-exempt employers. Non-THC urine panels and oral fluid saliva kits remain fully available for pre-employment screening. Employers must provide written notice of the testing policy before testing begins.
• Random testing: California places significant restrictions on suspicionless random drug testing for non-DOT private employers. Random programs require careful legal review to confirm they are supported by safety-sensitive position classifications or federal mandate. Employers outside those categories face meaningful litigation risk with broad random programs.
• Reasonable suspicion: California employers may test an employee based on documented, articulable observations of behavior, appearance, or conduct consistent with substance use or impairment. Written documentation by trained supervisors is essential. Oral fluid testing is increasingly preferred for reasonable suspicion because it targets recent impairment rather than historical exposure.
• Post-accident: Post-accident testing is generally supportable in California when the incident meets threshold severity criteria defined in the employer's written policy. Oral fluid testing is often the most appropriate specimen type because the detection window correlates most closely with impairment at the time of the incident.

---

10. Accuracy, Confirmation, and Chain of Custody

Point-of-care drug test cups and saliva kits are immunoassay screening devices. They deliver rapid presumptive results — not confirmed diagnoses. Any non-negative result from a point-of-care device should be confirmed by a SAMHSA-certified laboratory using GC-MS or LC-MS/MS confirmation testing before adverse employment action is taken. Medical Review Officer (MRO) review of non-negative results is best practice for employment programs and is required for DOT-regulated testing.

Chain of custody documentation begins at the point of collection. California employers who use point-of-care cups without collecting a split specimen and maintaining a proper chain of custody document create legal exposure if a terminated employee challenges the result. CLIA-waived urine cup programs should include a written collection procedure, chain of custody forms, and a defined protocol for shipping non-negative specimens to a confirmatory laboratory.

---

11. Employer Decision Framework: Choosing the Right Test for Your California Program

Rather than prescribing a single solution, the following framework guides California employers through the four key decisions that determine the right testing configuration:

---

12. 2027 California Employer Drug Testing Compliance Checklist

---